Aytu Biopharma (AYTU) Restructuring Costs (2020 - 2024)

Aytu Biopharma (AYTU) posted quarterly Restructuring Costs of $1.3 million for Q4 2024, up 67.98% quarter-over-quarter from $784000.0 in Q3 2024.

Aytu Biopharma (AYTU) Restructuring Costs (2020 - 2024) Analysis & Trends

Aytu Biopharma (AYTU) has reported Restructuring Costs for 3 consecutive years, with $1.3 million the latest figure, recorded in Q4 2024.

In Q4 2024, Restructuring Costs changed N/A year-over-year to $1.3 million; the TTM figure through Sep 2025 stood at $1.3 million (down 55.2% YoY), while the FY2025 annual figure was $2.1 million, down 2.55% from the prior year.
Restructuring Costs grew to $1.3 million in Q4 2024 per AYTU's latest filing, from $784000.0 in the prior quarter.
Across five years, Restructuring Costs topped out at $2.9 million in Q1 2021 and bottomed at -$2.0 million in Q2 2021.
Historically, Restructuring Costs has averaged $817233.6 across 3 years, with a median of $784000.0 in 2024.
On a YoY basis, Restructuring Costs climbed as much as 832.23% in 2021 and fell as far as 468.35% in 2021.
Aytu Biopharma's Restructuring Costs stood at $1.3 million in 2020, then slumped by 249.09% to -$2.0 million in 2021, then jumped by 167.33% to $1.3 million in 2024.
Business Quant data shows AYTU's Restructuring Costs at $1.3 million in Q4 2024, $784000.0 in Q3 2024, and $1.9 million in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.91 Bn	42.95 Bn	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.32 Bn	2.15 Bn
3	Zoetis	31.53 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.16 Bn	19.49 Bn	683.80 Mn
6	Viatris	18.74 Bn	17.85 Bn	1.46 Bn
7	Neurocrine Biosciences	15.51 Bn	15.12 Bn	935.80 Mn
8	Elanco Animal Health	11.76 Bn	11.23 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.12 Bn	9.95 Bn	-
10	Aytu Biopharma	24.60 Mn	-2.12 Mn	7.60 Mn

Download Data